A placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Introduction and Aims. As an antidepressant with sedative and anxiolytic properties, mirtazapine may be an appropriate pharmacotherapy for methamphetamine withdrawal. This study sought to examine whether mirtazapine improves retention and alleviates methamphetamine withdrawal symptoms in an out‐patient setting. Design and Methods. An out‐patient double‐blind, randomised placebo‐controlled trial of mirtazapine for the treatment of methamphetamine withdrawal was conducted (15 mg nocte for 2 days, 30 mg nocte for 12 days). Both groups were offered narrative therapy counselling. Measures recorded on days 0, 3, 7, 14 and 35 included: treatment retention, Amphetamine Cessation Symptoms Assessment, the Athens Insomnia Scale, the Brief Symptom Inventory, the Depression–Anxiety–Stress Scale (DASS), Severity of Dependence scale and the Opiate Treatment Index Drug Use subscale. Results. Thirty‐one participants were recruited (18 placebo, 13 mirtazapine) and 52% completed the 2‐week medication phase. No significant differences between the mirtazapine and placebo groups in retention, or any symptom measure were observed, except greater DASS–anxiety and longer sleep duration were measured at baseline among the mirtazapine group. Discussion and Conclusions. Results suggest that mirtazapine does not facilitate retention or recruitment in out‐patient methamphetamine withdrawal treatment, although recruitment may have been insufficient to identify a significant treatment effect. The potential role of narrative therapy for methamphetamine dependent patients deserves further exploration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Three medication studies showed significant reductions in craving ratings for MA: d-amphetamine 60mg/d for four weeks (48), combination of extended release naltrexone (380mg every 3 weeks) and bupropion (450mg q d; (49)) and rTMS (10HZ at left DPLFC, two 5-day sessions over 12 days (42)).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [42]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“one trial of repetitive transcranial magnetic stimulation (rTMS) (10HZ at left DPLFC, two 5-day sessions over 12 days (42))”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [42]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A third trial of mirtazapine (30mg/nocte for 14 days (43) showed no differences in withdrawal symptoms, though in this study all medications were self-administered at night and medication adherence problems may have interfered.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A third trial of mirtazapine (30mg/nocte for 14 days (43) showed no differences in withdrawal symptoms, though in this study all medications were self-administered at night and medication adherence problems may have interfered.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“No significant association with retention in out- patient withdrawal treatment”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Cruickshank, C.C. et al., 2008
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lovibond, P. F., & Lovibond, S. H. (1995) · Behaviour Research and Therapy · doi:10.1016/0005-7967(94)00075-u · Cited by 14,523
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
The brief symptom inventory: an introductory report.
Derogatis, L. R., & Melisaratos, N. (1983) · Psychological Medicine · doi:10.1017/s0033291700048017 · Cited by 6,650
Antony, M. M., Bieling, P. J., Cox, B. J., Enns, M. W., & Swinson, R. P. (1998) · Psychological Assessment · doi:10.1037/1040-3590.10.2.176 · Cited by 4,874
Athens Insomnia Scale: Validation of an instrument based on ICD-10 criteria
Soldatos, C. R., Dikeos, D. G., & Paparrigopoulos, T. J. (2000) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(00)00095-7 · Cited by 1,754
GOSSOP, M., DARKE, S., GRIFFITHS, P., HANDO, J., POWIS, B., HALL, W., & STRANG, J. (1995) · Addiction · doi:10.1046/j.1360-0443.1995.9056072.x · Cited by 1,343
Association of Dopamine Transporter Reduction With Psychomotor Impairment in Methamphetamine Abusers
Volkow, N. D., Chang, L., Wang, G.-J., Fowler, J. S., Leonido-Yee, M., Franceschi, D., Sedler, M. J., Gatley, S. J., Hitzemann, R., Ding, Y.-S., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.377 · Cited by 984
A Review of the Pharmacological and Clinical Profile of Mirtazapine
Anttila, S. A. K., & Leinonen, E. V. J. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00198.x · Cited by 795
The diagnostic validity of the Athens Insomnia Scale
Soldatos, C. R., Dikeos, D. G., & Paparrigopoulos, T. J. (2003) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(02)00604-9 · Cited by 661
Psychiatric Symptoms in Methamphetamine Users
Zweben, J. E., Cohen, J. B., Christian, D., Galloway, G. P., Salinardi, M., Parent, D., Iguchi, M., & Methamphetamine Treatment Project (2004) · The American Journal on Addictions · doi:10.1080/10550490490436055 · Cited by 468
Research works printed but not linked: 3
- McGregorC.Amphetamine withdrawal: nature time course and treatment[dissertation]. Adelaide South Australia:The University of Adelaide 2005.
- Derogatis LR., 1993, Brief symptom inventory administration, scoring, and procedures manual
- 10.1111/j.1360-0443.1997.tb02953.x · doi:10.1111/j.1360-0443.1997.tb02953.x · Paper page
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“However a more recent study failed to find any benefit of mirtazapine over placebo (Cruickshank et al., 2008) (Ib).”
BackgroundPharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Mirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175
“0 12 (27;27) 11 (23;23) 10 (23;23) 9 (26;24) 8 (27;24) 7 (26;25) 6 (26;27) 5 (27;22) 4 (27;27) 3 (25;23) 2 (28;27) 0 (30;30)”
A double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Shearer, J., Darke, S., Rodgers, C., Slade, T., Van Beek, I., Lewis, J., Brady, D., McKetin, R., Mattick, R. P., & Wodak, A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02437.x · Cited by 159
“Narrative therapy has also shown recent promise in methamphetamine users [44].”
Background
Metadata
- Authors
- CRUICKSHANK, C. C., MONTEBELLO, M. E., DYER, K. R., QUIGLEY, A., BLASZCZYK, J., TOMKINS, S., & SHAND, D.
- Affiliations
- The University of Western Australia (AU)
- UNSW Sydney (AU)
- Mental Health Commission (AU)
- Corresponding author
- CRUICKSHANK, CHRISTOPHER C.
- Venue
- Drug and Alcohol Review
- Publisher
- Wiley
- Published
- 2008-05
- Volume
- 27
- Issue
- 3
- Pages
- 326-333
- ISSN
- 0959-5236 (ISSN-L)
- 1465-3362
- OpenAlex
- W2142454789
- Cited by
- 74
- References
- 46
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 1 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 3 · 2017: 6 · 2016: 4 · 2015: 6 · 2014: 2 · 2013: 4 · 2012: 8
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Drug and Alcohol Review (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Medical Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- mirtazapine, methamphetamine withdrawal, treatment retention, narrative therapy, outpatient care, antidepressants, substance dependence, anxiety, sleep duration
- MeSH terms
- Mirtazapine, Adult, Ambulatory Care, Central Nervous System Stimulants, Antidepressive Agents, Tricyclic, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Methamphetamine, Mianserin, Psychiatric Status Rating Scales, Severity of Illness Index, Substance Withdrawal Syndrome, Time Factors, Amphetamine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal. https://app.cochat.ai/papers/10.1080/09595230801935672
- The paper
- CRUICKSHANK, C. C., MONTEBELLO, M. E., DYER, K. R., QUIGLEY, A., BLASZCZYK, J., TOMKINS, S., & SHAND, D. (2008). A placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug and Alcohol Review. https://doi.org/10.1080/09595230801935672
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.